MA41873B2 - Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof - Google Patents
Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereofInfo
- Publication number
- MA41873B2 MA41873B2 MA41873A MA41873A MA41873B2 MA 41873 B2 MA41873 B2 MA 41873B2 MA 41873 A MA41873 A MA 41873A MA 41873 A MA41873 A MA 41873A MA 41873 B2 MA41873 B2 MA 41873B2
- Authority
- MA
- Morocco
- Prior art keywords
- bind
- antibodies
- binding molecules
- bispecific antigen
- present
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des anticorps qui se lient à cd3 et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps de l'invention se lient à cd3 humain à affinité élevée et induisent la prolifération de lymphocytes t humains. L'invention comprend des anticorps qui se lient à cd3 et induisent la mort à médiation par des lymphocytes t de cellules tumorales. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à un antigène bisThe present invention relates to antibodies that bind to cd3 and methods of using them. In some embodiments, the antibodies of the invention bind to high affinity human cd3 and induce proliferation of human t cells. The invention includes antibodies that bind to cd3 and induce t-cell mediated death of tumor cells. Embodiments of the present invention relate to bis antigen-binding molecules
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261704029P | 2012-09-21 | 2012-09-21 | |
| PCT/US2013/060511 WO2014047231A1 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41873A1 MA41873A1 (en) | 2018-07-31 |
| MA41873B2 true MA41873B2 (en) | 2022-04-29 |
Family
ID=59745478
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41873A MA41873B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof |
| MA37998A MA37998B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37998A MA37998B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses |
Country Status (2)
| Country | Link |
|---|---|
| MA (2) | MA41873B2 (en) |
| PY (1) | PY1343212A (en) |
-
2013
- 2013-09-19 MA MA41873A patent/MA41873B2/en unknown
- 2013-09-19 MA MA37998A patent/MA37998B2/en unknown
- 2013-09-20 PY PY201301343212A patent/PY1343212A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA41873A1 (en) | 2018-07-31 |
| MA37998B2 (en) | 2020-07-29 |
| PY1343212A (en) | 2016-12-01 |
| MA37998A1 (en) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49043B1 (en) | STABLE ANTIBODY FORMULATION | |
| MA39313A1 (en) | Anti-egfrviii antibodies and their uses in the treatment of various cancers | |
| MA52773B1 (en) | ANTI-CD3 ANTIBODIES AND THEIR USES | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| MA34749B1 (en) | LOW AFFINITY HEMATO-ENCEPHALIC BARRIER ANTI-RECEPTOR ANTIBODIES AND USES THEREOF | |
| MA38632A1 (en) | Anti-transferrin receptor antibody and methods of use | |
| MA33402B1 (en) | Formulations and methods of targeting the complementary c3b antibody | |
| PH12020500667A1 (en) | Multispecific antibodies and use thereof | |
| MA34927B1 (en) | ANTI-ACE ANTIBODIES | |
| JOP20190133A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies | |
| MA39061A1 (en) | Aplnr modulators and their uses | |
| UA106070C2 (en) | Antibody that specifically binds to egfr and her3 | |
| MA35711B1 (en) | Anti-alphabetatcr antibodies | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| CL2019002953A1 (en) | Anti-pd-l1 antibody and its use. | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| PH12021552379A1 (en) | Anti-egfrviii antibodies and antigen-binding fragments thereof | |
| PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
| MX2020009864A (en) | Anti-cd137 antibodies for combination with anti-pd-1 antibodies. | |
| MX2023009434A (en) | Antibodies against cd112r and uses thereof. | |
| MA41873B2 (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof | |
| EA202091984A1 (en) | ZETAKIN DIRECTED T-CELL IMMUNOTHERAPY TARGETING THE IL-13 ALPHA 2 RECEPTOR | |
| MX2020009863A (en) | ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES. | |
| FR3077574B1 (en) | ANTIBODIES DIRECTED AGAINST ENDOTHELIN RECEPTOR SUBTYPE A AND THEIR USES. | |
| MA39751B1 (en) | Antibody compositions for the treatment of tumors |